What we are studying
The purpose of this study is to test the two drugs dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) together to see how well they work compared to two placebos. We want to find out what effects, good or bad, these two drugs have on people who have a type of skin cancer called melanoma. The study drugs dabrafenib and trametinib together are not yet approved for doctors to prescribe to patients.
Set amount for travel reimbursement on treatment days.